Peptide Mapping- A Comprehensive Workflow Solution from Sample to Answer

by | Sep 12, 2017

Learn how these technologies can help you save time, boost analytical productivity and performance, and be more confident with your peptide mapping data.

Biosim_eSem_icon.pngPeptide mapping is vital to understanding the structure of proteins and monitoring critical quality attributes. To create effective, high-quality biotherapeutics, you have to get this right. Renowned for accuracy and reliability, Agilent offers a comprehensive set of technologies to ensure that every element of your peptide mapping workflow performs as it should. Automation of sample preparation workflows can increase sample processing capacity, reduce variability, and eliminate the need for skilled labor to perform repetitive tasks. The Agilent AssayMAP Bravo sample prep platform combines automation and an optimized workflow interface to provide superior efficiency and reproducibility.

The Agilent peptide mapping workflow solution integrates state of the art liquid handling robotics, high performance chromatography technologies, accurate-mass Q-TOF LC/MS, and powerful MassHunter BioConfirm software to automate and streamline a complex process that is critical to the development of mAb biologics. Learn how these technologies can help you save time, boost analytical productivity and performance, and ultimately, be more confident with your peptide mapping data.

Separation Science, in collaboration with Agilent Technologies, has developed an eSeminar covering the analysis of biotherapeutics and biosimilars. 

NingTang.pngThis presentation is given by Ning Tang (Biopharma Segment Marketing Manager, Agilent Technologies)


By attending this presentation you will learn about...

  • The Agilent peptide mapping workflow solution integrates state of the art liquid handling robotics, high performance chromatography technologies, accurate-mass Q-TOF LC/MS, and powerful software to automate and streamline a complex process that is critical to the development of mAb biologics.

Related Content

Advertisment

Advertisment

Advertisement